Patrick Wood
Stock Analyst at Morgan Stanley
(2.13)
# 2,864
Out of 5,182 analysts
121
Total ratings
41.67%
Success rate
-2.91%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $23 → $25 | $19.18 | +30.34% | 7 | Mar 2, 2026 | |
| MDLN Medline | Maintains: Overweight | $48 → $52 | $45.60 | +14.04% | 2 | Mar 2, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $80 → $85 | $73.18 | +16.15% | 9 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $130 → $118 | $61.79 | +90.97% | 8 | Feb 5, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $71.21 | +16.56% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $114.00 | +18.42% | 3 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $6.83 | +46.41% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $23.20 | +119.83% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $64.02 | +17.15% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $154.22 | +36.17% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $19 → $15 | $17.15 | -12.54% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $14 → $21 | $16.49 | +27.35% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $78.01 | +2.55% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $222.58 | +32.54% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $77.87 | +4.02% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $65.79 | +56.56% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $116.40 | -38.14% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $118.39 | +46.13% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $196.93 | +60.97% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $26.44 | +39.94% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $150.05 | - | 5 | Dec 11, 2017 |
Tandem Diabetes Care
Mar 2, 2026
Maintains: Equal-Weight
Price Target: $23 → $25
Current: $19.18
Upside: +30.34%
Medline
Mar 2, 2026
Maintains: Overweight
Price Target: $48 → $52
Current: $45.60
Upside: +14.04%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $73.18
Upside: +16.15%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $130 → $118
Current: $61.79
Upside: +90.97%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $71.21
Upside: +16.56%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $114.00
Upside: +18.42%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $6.83
Upside: +46.41%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $23.20
Upside: +119.83%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $64.02
Upside: +17.15%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $154.22
Upside: +36.17%
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $17.15
Upside: -12.54%
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $16.49
Upside: +27.35%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $78.01
Upside: +2.55%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $222.58
Upside: +32.54%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $77.87
Upside: +4.02%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $65.79
Upside: +56.56%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $116.40
Upside: -38.14%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $118.39
Upside: +46.13%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $196.93
Upside: +60.97%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $26.44
Upside: +39.94%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $150.05
Upside: -